{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:22:47Z","timestamp":1783074167530,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundacion Cientifica de la Asociacion Espanola Contra el Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["PERME19002RODR"],"award-info":[{"award-number":["PERME19002RODR"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019904","name":"Santander Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Community of Madrid","doi-asserted-by":"publisher","award":["PEJ-2023-AI\/SAL-GL- 27634"],"award-info":[{"award-number":["PEJ-2023-AI\/SAL-GL- 27634"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Community of Madrid","doi-asserted-by":"publisher","award":["PIPF-2022\/SAL-GL-25283"],"award-info":[{"award-number":["PIPF-2022\/SAL-GL-25283"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTC2019\\u2013007359\\u20131"],"award-info":[{"award-number":["RTC2019\\u2013007359\\u20131"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CPP2022\\u2013009545"],"award-info":[{"award-number":["CPP2022\\u2013009545"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01223"],"award-info":[{"award-number":["PI22\/01223"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/01054"],"award-info":[{"award-number":["PI23\/01054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","award":["AC19\/00026"],"award-info":[{"award-number":["AC19\/00026"]}],"id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.phrs.2026.108232","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:09:40Z","timestamp":1777964980000},"page":"108232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients"],"prefix":"10.1016","volume":"228","author":[{"given":"Cristina","family":"Mart\u00ednez-Toledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Jim\u00e9nez-Meseguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Molina-Alejandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Collazo-Lorduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierra-Rodero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00ednez Cutillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Gil-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Guti\u00e9rrez-Escobedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"V\u00e1zquez Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fern\u00e1ndez N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Diz-Ta\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Garrido Onecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pe\u00f1a-Cabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sequero-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Rogado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"S\u00e1nchez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Coves Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Sala Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Mielgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa D.","family":"Garc\u00eda Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Garc\u00eda-Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-7011","authenticated-orcid":false,"given":"Alberto","family":"Cruz-Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108232_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.108232_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non\u2013Small Cell Lung Cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2026.108232_bib3","first-page":"10","article-title":"Cancer statistics, 2025","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin. [Internet]"},{"key":"10.1016\/j.phrs.2026.108232_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193262","article-title":"Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108232_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108232_bib7","first-page":"1657","article-title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020"},{"key":"10.1016\/j.phrs.2026.108232_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108232_bib9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase i KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108232_bib10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108232_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108232_bib12","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108232_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med. Mass. Med. Soc."},{"key":"10.1016\/j.phrs.2026.108232_bib14","first-page":"345","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021"},{"key":"10.1016\/j.phrs.2026.108232_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12140","article-title":"Population Pharmacokinetic\/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma","volume":"6","author":"Chatterjee","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.phrs.2026.108232_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108232_bib17","article-title":"Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review","volume":"97","author":"Cheng","year":"2021"},{"key":"10.1016\/j.phrs.2026.108232_bib18","first-page":"1393","article-title":"Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure\u2013Response Relationships","volume":"58","author":"Leven","year":"2019"},{"key":"10.1016\/j.phrs.2026.108232_bib19","first-page":"68","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020"},{"key":"10.1016\/j.phrs.2026.108232_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12132","article-title":"Using Model-Based \u201cLearn and Confirm\u201d to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial","volume":"6","author":"Elassaiss-Schaap","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.phrs.2026.108232_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.808","article-title":"Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers","volume":"9","author":"Navani","year":"2021","journal-title":"Pharm. Res Perspect."},{"key":"10.1016\/j.phrs.2026.108232_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cpt.3339","article-title":"Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older","volume":"116","author":"Yagishita","year":"2024","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2026.108232_bib23","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Exposure-Response Relationships \u2014 Study Design, Data Analysis, and Regulatory Applications. 2003."},{"key":"10.1016\/j.phrs.2026.108232_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lungcan.2023.02.009","article-title":"Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial","volume":"178","author":"Wang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2026.108232_bib25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108232_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005132","article-title":"Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis","volume":"10","author":"Mallardo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108232_bib27","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1177\/10781552231212926","article-title":"Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer","volume":"30","author":"Chaitesipaseut","year":"2024","journal-title":"J. Oncol. Pharm. Pr. J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.phrs.2026.108232_bib28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/cancers17071147","article-title":"Fixed-Dose Versus Weight-Adapted Immune Checkpoint Inhibitor Therapy in Melanoma: A Retrospective Monocentric Analysis of Efficacy and Immune-Related Adverse Events","volume":"17","author":"Staender","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108232_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J. Immunother. Cancer J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108232_bib30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc Receptor \u2014 Biology and Therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108232_bib31","first-page":"15","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018"},{"key":"10.1016\/j.phrs.2026.108232_bib32","first-page":"857","article-title":"Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications","volume":"59","author":"Bensalem","year":"2020"},{"key":"10.1016\/j.phrs.2026.108232_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","article-title":"A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor \u03b1-chain promoter","volume":"119","author":"Sachs","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2026.108232_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/rco2.32","article-title":"Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans","volume":"4","author":"Castillo","year":"2021","journal-title":"JCSM Rapid Commun."},{"key":"10.1016\/j.phrs.2026.108232_bib35","series-title":"Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non\u2013Small Cell Lung Cancer","first-page":"692","author":"Li","year":"2019"},{"key":"10.1016\/j.phrs.2026.108232_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002344","article-title":"Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors","volume":"9","author":"Hurkmans","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108232_bib37","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab Exposure\u2013Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2026.108232_bib38","first-page":"35","article-title":"Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients","volume":"173","author":"Ohuchi","year":"2022"},{"key":"10.1016\/j.phrs.2026.108232_bib39","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/ijc.70052","article-title":"Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer","author":"de Vries","year":"2025","journal-title":"Int J. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:03:48Z","timestamp":1783073028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S1043661826001477"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108232","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108232"}}